Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have received an average rating of “Moderate Buy” from the nine brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $64.4286.

A number of analysts have weighed in on the company. Wedbush restated an “outperform” rating and set a $46.00 target price on shares of Dianthus Therapeutics in a report on Monday, December 22nd. HC Wainwright increased their price objective on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Truist Financial raised their target price on Dianthus Therapeutics from $56.00 to $63.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, January 21st.

Insider Activity

In related news, CFO Ryan Savitz sold 20,000 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $45.18, for a total transaction of $903,600.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Simrat Randhawa sold 109,031 shares of Dianthus Therapeutics stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $38.14, for a total transaction of $4,158,442.34. Following the transaction, the executive vice president directly owned 4,000 shares of the company’s stock, valued at approximately $152,560. This trade represents a 96.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 216,538 shares of company stock worth $8,283,175. 8.15% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Parkside Financial Bank & Trust grew its position in shares of Dianthus Therapeutics by 131.7% in the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock valued at $37,000 after purchasing an additional 540 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Dianthus Therapeutics in the second quarter valued at approximately $27,000. Russell Investments Group Ltd. purchased a new position in Dianthus Therapeutics in the third quarter worth approximately $64,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Dianthus Therapeutics during the fourth quarter worth $135,000. Finally, Tower Research Capital LLC TRC increased its stake in Dianthus Therapeutics by 330.7% during the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after acquiring an additional 3,317 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Price Performance

Shares of DNTH opened at $53.39 on Friday. The company has a 50-day moving average of $43.79 and a 200 day moving average of $35.02. Dianthus Therapeutics has a 1-year low of $13.36 and a 1-year high of $57.50. The firm has a market capitalization of $2.31 billion, a price-to-earnings ratio of -15.34 and a beta of 1.55.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.11). Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%.The firm had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.58 million. On average, equities analysts anticipate that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.